Physiological analysis of 8-Iso-PGF2 alpha: A homeostatic agent in superficial bladder cancer

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 1, 2011, Pages 71-76

  Verratti, Vittore ^a   Brunetti, L ^a   Tenaglia, R ^a   Chiavaroli, A ^a   Ferrante, C ^a   Leone, S ^a   Orlando, G ^a   Berardinelli, F ^a   Di Giulio, C ^a   Vacca, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

8 Iso PGF2 alpha; Homeostatic agent; Oxygen supply; Superficial bladder cancer

Indexed keywords

PROSTAGLANDIN F2 ALPHA; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; VASOCONSTRICTOR AGENT;

ARTICLE; BLADDER CANCER; BLADDER MUCOSA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RELEASE; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; SUPERFICIAL BLADDER CANCER; VASOCONSTRICTION; BIOSYNTHESIS; BLADDER; BLADDER TUMOR; DRUG EFFECT; FEMALE; MALE; METABOLISM; MUCOSA; OXYGEN CONSUMPTION; PATHOLOGY; TUMOR CELL CULTURE; VASODILATATION;

DINOPROST; FEMALE; HUMANS; MALE; MUCOUS MEMBRANE; OXYGEN CONSUMPTION; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 79955672260     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol 2003; 18:259-74. (Pubitemid 36040467)
2. Eble JN, Young RH. Carcinoma of the urinary bladder: A review of its diverse morphology. Semin Diagn Pathol 1997; 14:98-108. (Pubitemid 27233148)
3. Reuter VE. The pathology of bladder cancer. Urology 2006; 67:11-17.
4. Dinney CP, McConkey DJ, Millikan RE, et al. Cancer Cell 2004; 6:111-6.
5. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998; 8:143-50. (Pubitemid 28323473)
6. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-83. (Pubitemid 32059187)
7. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6:157-62. (Pubitemid 30171366)
8. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28:36-41. (Pubitemid 32522236)
9. Harris AL. Hypoxia a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47. (Pubitemid 37328806)
10. Vaupel PW. Oxygenation of solid tumors. In Drug Resistance in Oncology. Marcel Dekker, Teicher BA ed. New York 1993; 53-85.
11. Gulledge CJ, Dewhirst MW. Tumor oxygenation: a matter of supply and demand. Anticancer Res 1996; 16:741-49. (Pubitemid 26182004)
12. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995; 34:313-6.
13. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. Hypoxia inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94:8104-9. (Pubitemid 27343784)
14. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-40. (Pubitemid 33063099)
15. Zhong H, De Marzo AM, Laughner E, et al. Over expression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-35.
16. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157:411-42.
17. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55:510-13.
18. Van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann NY Acad Sci USA 2000; 936:426-37. (Pubitemid 32613925)
19. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
20. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22:6549-56. (Pubitemid 37372334)
21. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20:3906-27.
22. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 1995; 9:1233-43.
23. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst-MW. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996; 56:5522-28. (Pubitemid 27011389)
24. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 1995; 71:1210-13.
25. Porter NA, Funk MO. Peroxyl radical cyclization as a model for prostaglandin biosynthesis. J Org Chem 1975; 40:3614-15.
26. Morrow JD, Minton TA, Roberts LJII. The F2-isoprostane, 8-epi-prostaglandin F2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992; 44:155-63.
27. Brunetti L, Leone S, Orlando G, Recinella L, Ferrante C, Chiavaroli A, Di Nisio C, Verratti V, Vacca M. Cafeteria diet increases prostaglandin E2 levels in rat prostate, kidney and testis. Int J Immunopathol Pharmacol 2010; 23:1073-8.
28. Wang Z, Ciabattoni G, Créminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2alpha excretion in man. J Pharmacol Exp Ther 1995; 275:94-100.
29. Chiavaroli A, Brunetti L, Orlando G, Recinella L, Ferrante C, Leone S, Di Michele P, Di Nisio C, Vacca M. Resveratrol inhibits isoprostane production in young and aged rat brain. J Biol Regul Homeost Agents 2010; 24:441-6.
30. Youssef RF, Mitra AP, Bartsch G Jr, Jones PA, Skinner DG, Cote RJ. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009; 27:9-20.
31. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
32. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nature Rev Cancer 2003; 3:401-10. (Pubitemid 37328844)
33. Friesenecker B. Does the vessel wall partition oxygen away from the tissue? Antioxid Redox Signal 2007; 9:985-89. (Pubitemid 46919599)
34. Tsai AG, Friesenecker B, Cabrales P, Hangai-Hoger N, Intaglietta M. The vascular wall as a regulator of tissue oxygenation. Curr Opin Nephrol Hypertens 2006; 15:67-71.
35. Verratti V, Di Giulio C, Berardinelli F, et al. Pampiniform plexus and oxidative stress during chronic hypoxia and hyperoxia. Int J Immunopathol Pharmacol 2008; 21:353-7. (Pubitemid 351988397)
36. Verratti V, Di Giulio C, Berardinelli F, Brunetti L, Orlando G, Vacca M, Ferrante C, Nicolai M, Tenaglia R. Oxidative stress in testis of neonatal, young adult and aged rat. Andrology Update 2007; 1:1-7.